Fragile X syndrome is caused by loss of expression of FMRP, a protein proposed to act as a regulator of mRNA translation which promotes synaptic maturation and function. Now FMRP has been found to associate with the RNP complex that mediates posttranscriptional silencing by RNAi. 
RNAi is a conserved gene-silencing response to double-stranded RNA (dsRNA), which mediates resistance to both endogenous and exogenous parasitic nucleic acids, encoded by transposons and viruses, respectively (reviewed in [11] ). RNAi also regulates the expression of cellular protein-coding genes. A signature feature of RNAi is the formation of small RNAs, 21-23 nucleotides in length, which are generated by a class of conserved RNase III enzymes called the DICER family (Figure 1) . DICER recognizes and cleaves dsRNA molecules to produce 21-23 nucleotide fragments [12] . It has been shown that these fragments, called short interfering RNAs (siRNAs), can substitute for dsRNA in stimulating degradation of homologous mRNAs, the primary mechanism of gene silencing in RNAi [13] . Thus, siRNAs are thought to be the direct guides that identify homologous mRNA substrates for degradation. DICER also processes short hairpin RNAs transcribed from endogenous genes [11] , producing 21 nucleotide single-stranded micro-RNAs (miRNAs). In contrast to the siRNA pathway, miRNAs can silence gene expression by repressing translation of complementary mRNA transcripts [14, 15] . There are estimated to be possibly hundreds of miRNA-encoding genes in the genome [16] .
Biochemical analysis using Drosophila extracts has revealed how siRNAs interact with mRNA substrates ( Figure 1A) . It was observed that siRNAs associate into a nuclease complex dubbed RISC which rec-ognizes and cleaves homologous mRNAs [17] . The cleavage reaction is endonucleolytic and occurs at a central site in the region homologous to the siRNA [13] . One of the subunits of RISC is AGO2 [18] , the same protein found by Ishizuka et al.
[7] to associate with dFMR1. At the same time, Caudy et al. [19] were identifying proteins associated with RISC activity from partially purified Drosophila preparations, and found that dFMR1 is one such associated factor. Together, these initial observations suggested that dFMR1 may be involved in RNAi.
The two groups [7,19] report a variety of experimental evidence in support of this idea. dFMR1 coimmunoprecipitates with AGO2 and another RISC protein (VIG) from Drosophila cell lysates. Moreover, both a miRNA (miR-2b) and siRNAs can co-immunoprecipitate with dFMR1, consistent with the view that dFMR1 associates with RISC. The most compelling biochemical evidence, provided by Caudy et al. [19] , is that immunoprecipitates of dFMR1 from dsRNAchallenged cells have RISC activity. What is clear is that dFMR1 is not an essential factor for RNAi-mediated degradation. Rather than being a constitutive component of transcript-cleaving RISC, dFMR1 might be an accessory factor that associates with RISC but uses another mechanism to regulate its targets. This interpretation fits nicely with the other mechanism being translational repression, as dFMR1 and FMRP have been shown to repress translation of select mRNAs, as do some miRNAs [3,9,14,15,20]. Because miRNAs and dFMR1 interact with each other as well as with RISC, it is quite possible that dFMR1 is targeted to substrate transcripts as part of a RISC complex that is guided by miRNAs. Thus, a RISC core might interact with different combinations of RNA and protein accessory factors to carry out either transcript cleavage or translation control.
All this suggests that dFMR1 is intimately associated with RISC in
An alternative scenario is that dFMR1-associated RISC complexes may only use a subset of trigger siRNAs or miRNAs available. dFMR1 itself may contribute to such RNA specificity, as FMRP was found to selectively bind RNA oligonucleotides with G-quartet structures adjacent to short RNA helices [3,20]. While it was originally proposed that FMRP directly binds to mRNA substrates with these structural features, FMRP may instead recognize specific miRNAs with these features, which then guide FMRP to its correct targets. It is possible that some, but not all, siRNAs associate with FMRP and guide RISC complexes that are competent to degrade mRNA as well.
The connection between the RNAi and fragile X fields is likely to grow as we find out which small RNAs mediate translational repression by dFMR1 and FMRP, and how the repressive mechanism operates. Nevertheless, it is worth pondering that fragile X syndrome may be the result of a defect in the RNAi activity within neurons, making its molecular nature a RISCy business. 
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